

Dated: June 8, 2000.

Carolyn J. Russell,

*Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.*

[FR Doc. 00-14949 Filed 6-13-00; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[Program Announcement 00146]

Cooperative Agreement With the Kenya Medical Research Institute; Notice of Availability of Funds

A. Purpose

The Centers for Disease Control and Prevention (CDC) announces the availability of funds for fiscal year (FY) 2000 for a cooperative agreement program with the Kenya Medical Research Institute (KEMRI) to conduct complex research studies and related activities to control and prevent malaria, HIV/AIDS, and other diseases of public health importance in Kenya. CDC is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2010", a national activity to reduce morbidity and mortality and improve the quality of life. This announcement is related to the focus areas of HIV and Immunization and Infectious Diseases. For the conference copy of "Healthy People 2010", visit the internet site <http://www.health.gov/healthypeople>.

The objectives of this proposal are:

1. To assist KEMRI in the conduct of field and laboratory research on important human infectious diseases prevalent in Kenya with an emphasis on malaria and HIV.

2. To improve the training of students and public health professionals in basic and applied public health research and the training of students and other professionals in the areas that provide support to research efforts such as data and financial management.

3. To strengthen KEMRI institutional capacity to conduct research and training in public health.

4. To incorporate the results of research into operational disease prevention and control programs in the Republic of Kenya and insure sharing of expertise and research findings with other nations.

5. To determine national priority areas and develop human resources focused on public health.

B. Eligible Applicants

Assistance will be provided only to KEMRI. No other applications are solicited. KEMRI is the most appropriate and qualified agency to conduct the activities specified under this cooperative agreement because:

1. KEMRI is the only research organization in Kenya that possesses the requisite scientific and technical expertise, the infrastructure capacity and who has conducted longitudinal malaria and related HIV research in areas of high morbidity (20 years for malaria and 10 years for HIV/AIDS). These combined attributes make them the only organization in Kenya capable of effectively conducting the research proposed for this cooperative agreement.

2. A major operational unit of KEMRI is located in western Kenya in an area of extremely high level malaria and HIV transmission, and thus is ideally located to evaluate approaches to preventing and controlling these public health problems.

3. KEMRI was established through the Science and Technology Act of the Republic of Kenya and has a Board of Management appointed by the Minister of Health which is responsible for overseeing all research and which has a well-developed secretariat to provide administrative and technical support to research services.

4. KEMRI has been collaborating with health agencies on priority infectious disease research for over 20 years on the grounds of the KEMRI facility both in Nairobi and Kisumu. The KEMRI Facility has experienced staff, equipment, and facilities to support the collaboration.

C. Availability of Funds

Approximately \$657,000 is available in FY 2000 to fund one award. It is expected that \$574,000 will be available for malaria and infectious diseases and \$83,000 will be for HIV/AIDS. It is expected that the award will begin on August 1, 2000, and will be made for a 5-month budget period within a project period of up to five years. The funding estimate may change.

Continuation awards within an approved project period will be made on the basis of satisfactory progress as evidenced by required reports and the availability of funds.

Use of Funds

Indirect costs will not be provided on HHS Grants to international or foreign organizations where the grant is performed entirely outside the territorial limits of the United States.

D. Where to Obtain Additional Information

If you have any questions after reviewing the content of all documents, business management technical assistance may be obtained from: Juanita D. Crowder, Grants Management Specialist, Grants Management Branch, Procurement and Grants Office, Centers for Disease Control and Prevention, Room 3000, 2920 Brandywine Road, Atlanta, GA 30341-4146, Telephone: (770)488-2734, Email address: jdd2@cdc.gov.

For program technical assistance, contact: Sue Binder, M.D., Division of Parasitic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention 1600 Clifton Road, Mailstop F-22, Atlanta, GA 30333, Telephone: (770)488-7793, Email address: sbinder@cdc.gov.

Dated: June 8, 2000.

Henry S. Cassell, III,

*Acting Director, Procurement and Grants
Office, Centers for Disease Control and
Prevention (CDC).*

[FR Doc. 00-14950 Filed 6-13-00; 8:45 am]

BILLING CODE 4162-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[Program Announcement 00098]

Grant To Support Natural Products Research on Phytomedicines at The University of Mississippi; Notice of Availability of Funds

A. Purpose

The Centers for Disease Control and Prevention (CDC) announces the availability of fiscal year (FY) 2000 funds for a grant program to Support Natural Products Research on Phytomedicines at the University of Mississippi.

B. Eligible Applicant(s)

Single Source

Assistance will be provided only to the National Center for Natural Products Research, Thad Cochran Research Center, University of Mississippi. No other applications are solicited. The Conference Report accompanying Public Law 106-113 (H.R. 3194), Consolidated Appropriations Act, 2000, found at H.R. Rep. No. 106-479, at 599 (1999) specified these funds for the University of Mississippi to establish a program to identify candidate phytomedicines for clinical evaluation.

C. Availability of Funds

Approximately \$1,823,000 is available in FY 2000 to fund one award. It is expected that the award will begin on or about September 30, 2000 and will be made for a 12-month budget period within a project period of up to three years.

D. Where To Obtain Additional Information

Business management technical assistance may be obtained from: Van A. King, Grants Management Specialist, Grants Management Branch, Procurement and Grants Office, Centers for Disease Control and Prevention (CDC), Announcement [00098], 2920 Brandywine Road, Room 3000, Atlanta, GA 30341, Telephone Number (770) 488-2751, Email Address vbk5@cdc.gov.

Program technical assistance may be obtained from: Earl Ford, Division of Nutrition and Physical Activity, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention (CDC), 4770 Buford Highway, MS K-26, Atlanta, GA 30341-3724, Telephone Number (770) 488-6015, Email Address EFord@cdc.gov.

Dated: June 8, 2000.

Henry S. Cassell, III,

Acting Director, Procurement and Grants Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 00-14943 Filed 6-13-00; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES**Centers for Disease Control and Prevention**

[Program Announcement 00104]

National Tuberculosis Controllers Association; Notice of Availability of Funds**A. Purpose**

The Centers for Disease Control and Prevention (CDC) announces the availability of fiscal year (FY) 2000 funds for a cooperative agreement program for the National Tuberculosis Controllers Association (NTCA). This program addresses the "Healthy People 2010", priority area of Immunization and Infectious Diseases.

The purpose of this program is to: (1) Maintain an effective communication capacity among the nation's tuberculosis (TB) control officials (TB Controllers) and TB nursing professionals; (2) to sustain a capacity

for coordinating the rapid, comprehensive assessment of problems and opportunities in the field of TB prevention and control; (3) to maintain the capacity to coordinate the consultations and collaborations that produce a front line perspective on the fast moving programmatic, scientific, and technological issues affecting the goal of TB elimination; (4) to assist in identifying TB training needs; and (5) to continue the capacity for cataloging and tracking the public and private assets of the nation's TB elimination effort.

B. Eligible Applicants

Assistance will be provided only to the National Tuberculosis Controllers Association (NTCA). No other applications are solicited.

NTCA is the only organization that has an established relationship with state and local health department TB prevention and control programs, access to TB Controllers and TB nursing professionals, and expertise which is necessary to carry out the project. NTCA is a unique organization because of the technical expertise of its members, especially relating to its application amidst the complex and changing environment of front line health care delivery.

Note: Public Law 104-65 states that an organization described in section 501(c)(4) of the Internal Revenue Code of 1986 that engages in lobbying activities is not eligible to receive Federal funds constituting an award, grant, cooperative agreement, contract, loan, or any other form.

C. Availability of Funds

Approximately \$150,000 will be available in FY 2000 to fund this award. It is expected that the award will begin on or about September 30, 2000, and will be made for a 12-month budget period within a project period of up to 5 years. Funding estimates may change.

Continuation awards within an approved project will be made on the basis of satisfactory progress as evidenced by required reports and the availability of funds.

D. Where To Obtain Additional Information

This and other CDC announcements can be found on the CDC home page Internet address—<http://www.cdc.gov>. Click on "Funding" then "Grants and Cooperative Agreements". An application kit will be provided to NTCA.

If you have questions after reviewing the contents of all the documents, business management technical assistance may be obtained from: Carrie Clark, Grants Management Specialist,

Grants Management Branch, Procurement and Grants Office, Centers for Disease Control and Prevention, Room 3000, 2920 Brandywine Road, Atlanta, GA 30341-4146, Telephone: (404) 488-2783, E-Mail Address: zri4@cdc.gov.

For program technical assistance, contact: John Seggerson, Office of the Director, Division of Tuberculosis Elimination, National Center for HIV, STD, and TB Prevention, Mail Stop E-10, Atlanta, GA 30333, Telephone: (404) 639-5328, E-Mail Address: jjjs1@cdc.gov.

Dated: June 8, 2000.

Henry S. Cassell, III,

Acting Director, Procurement and Grants Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 00-14948 Filed 6-13-00; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES**Centers for Disease Control and Prevention****Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Research To Strengthen Occupational Safety and Health Surveillance, RFA OH-00-005**

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following meeting.

Name: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Research to Strengthen Occupational Safety and Health Surveillance, RFA OH-00-005.

Times and Dates:

9 a.m.-9:30 a.m., July 10, 2000 (Open).
9:30 a.m.-5 p.m., July 10, 2000 (Closed).
8 a.m.-Noon, July 11, 2000 (Closed).

Place: Embassy Suites, 1900 Diagonal Road, Alexandria, Virginia 22314.

Status: Portions of the meeting will be closed to the public in accordance with provisions set forth in section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Associate Director for Management and Operations, CDC, pursuant to Public Law 92-463.

Matters to be Discussed: The meeting will include the review, discussion, and evaluation of applications received in response to RFA-OH-00-005.

Contact Person for More Information:

Michael J. Galvin, Jr., Ph.D., Health Science Administrator, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, 1600 Clifton Road, N.E., m/s D30 Atlanta, Georgia 30333. Telephone 404/639-3525, e-mail mtg3@cdc.gov.